Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 3/20 | 0.41 |
| ▸ | PGK2 | P07205 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthalene SCHEMBL1680172 | 0.87 | CYP2A6 (0.57) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL19062554 | 0.87 | CYP2A6 (0.57) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL3796240 | 0.87 | CYP2A6 (0.57) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL30445823 | 0.87 | CYP2A6 (0.57) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL30423233 | 0.87 | CYP2A6 (0.57) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL28848051 | 0.84 | CYP2A6 (0.53) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL28905256 | 0.81 | CYP2A6 (0.50) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL28217536 | 0.81 | CYP2A6 (0.50) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL30716582 | 0.79 | GPR84 (0.50) | CYP2A6ALOX12CA2CA4CA5A | |
| Naphthalene SCHEMBL28237204 | 0.79 | GPR84 (0.50) | CYP2A6ALOX12CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101987082-B | Solid preparation and preparation method thereof | ZHONG SHUGUANG | 2013-04-03 | — | — | CN | claimed |
| CN-101987082-A | Solid preparation and preparation method thereof | SHUGUANG ZHONG | 2011-03-23 | — | — | CN | claimed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| CN-101987082-B | Solid preparation and preparation method thereof | ZHONG SHUGUANG | 2013-04-03 | — | — | CN | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| CN-101987082-A | Solid preparation and preparation method thereof | SHUGUANG ZHONG | 2011-03-23 | — | — | CN | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | CYP2A6 2491/4885ALOX12 3655/4885CA2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.